Stock prices for tri-county biotech companies have spiked since an announcement July 6 that an Alzheimer’s drug developed by Biogen showed positive results in a large clinical trial, raising hopes for treatment of a disease that has befuddled researchers for decades. Thousand Oaks-based Amgen climbed as high as $196.15 and was up $5.78 per share…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
